COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsK. Ulrich BAYER, Steve Coultrap
Life of this patent
Estimating the term…
Abstract
Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
Claims19
A method for treating a subject having or suspected of developing a condition causing neuronal cell death comprising:
- administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more of a peptide consisting of SEQ ID NO:23 and SEQ ID NO:24;
- and a pharmaceutically acceptable derivative or salt thereof.
A method for treating a subject having or suspected of developing a drug addiction comprising:
- administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more of a peptide consisting of SEQ ID NO:23 and SEQ ID NO:24;
- and a pharmaceutically acceptable derivative or salt thereof.
A method for treating a subject having a traumatic brain injury comprising:
- administering to a subject a therapeutically effective amount of a composition comprising one or more of a peptide consisting of SEQ ID NO:23 and SEQ ID NO:24;
- and a pharmaceutically acceptable derivative or salt thereof.
The method of claim 17, wherein the traumatic brain injury comprises a traumatic brain injury due to a stroke, ischemia, Alzheimer's disease, Parkinson's disease, spinal cord injury, or drug addiction.
A method for treating a subject having cancer comprising, administering to a subject a therapeutically effective amount of a composition comprising one or more of a peptide consisting of SEQ ID NO:23 and SEQ ID NO:24;
- and a pharmaceutically acceptable derivative or salt thereof to reduce viable cancer cells;
- and treating the subject.
Dependencies are inferred from the claim text.